Table 1 Clinicopathological characteristics of first breast cancer for women who opted for CPM and women under surveillancea
Characteristic | CPM group ( N =79) | Surveillance group ( N =69) | P -value |
|---|---|---|---|
Age at first breast cancer (years) | |||
Mean±s.e. | 38.0±0.9 | 39.4±1.0 | 0.295 |
Range | 26–56 | 25–64 | |
Year of diagnosis | |||
Mean | 1995 | 1991 | <0.001 |
Median | 1997 | 1993 | |
Range | 1982–2002 | 1972–2002 | |
Breast cancer stage | |||
Stage I | 32 (40.5) | 25 (36.2) | 0.324 |
Stage IIa | 31 (39.2) | 27 (39.1) | |
Stage IIb | 10 (12.7) | 15 (21.7) | |
Stage IIIa | 6 (7.6) | 2 (2.9) | |
Pathological T stage (cm) | |||
T1: ⩽2 | 43 (54.4) | 38 (55.1) | 0.677 |
T2: 2–5 | 33 (41.8) | 30 (43.5) | |
T3: >5 | 3 (3.8) | 1 (1.4) | |
Axillary status | |||
Node negative | 52 (65.8) | 40 (58.0) | 0.495 |
Node positive | 27 (34.2) | 29 (42.0) | |
Bloom & Richardson grade | |||
Grade I | — (0.0) | 1 (2.1) | 0.481 |
Grade II | 22 (32.4) | 16 (33.3) | |
Grade III | 46 (67.6) | 31 (64.6) | |
Morphology | |||
Ductal | 68 (89.5) | 49 (75.4) | 0.042 |
Other | 8 (11.5) | 16 (24.6) | |
Estrogen receptor status | |||
Positive | 15 (26.3) | 17 (44.7) | 0.078 |
Negative | 42 (73.7) | 21 (55.3) | |
Progesterone receptor status | |||
Positive | 12 (22.6) | 12 (33.3) | 0.332 |
Negative | 41 (77.4) | 24 (66.7) | |
Therapy | |||
Breast-conserving surgery | 21 (26.6) | 41 (59.4) | <0.001 |
Radiotherapy | 46 (58.2) | 58 (84.1) | 0.001 |
Chemotherapy | 46 (58.2) | 26 (37.7) | 0.014 |
Hormonal therapy | 15 (19.0) | 4 (5.8) | 0.025 |
